Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Stocks rack up the records, dollar sings the blues

Published 11/26/2020, 07:46 PM
Updated 11/27/2020, 05:26 AM
© Reuters. TV camera men wait for the opening of market in front of a large screen showing stock prices at the Tokyo Stock Exchange in Tokyo

By Marc Jones

LONDON (Reuters) - World stocks remained on course for their best month ever on Friday as recent vaccine progress, Joe Biden's U.S. presidential election win, hopes for further stimulus, a commodity surge and a weak dollar all lifted the spirits.

European markets had a touch of caution ahead of a barrage of economic data and as questions emerged over trial data on AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine, but that wasn't going to derail a November to remember.

Germany's, France's, Italy's and Spain's main bourses all squeezed out gains and government bond yields stayed lows after the European Central Bank reinforced expectations of further stimulus next month.

London's FTSE was fractionally lower with some last-minute Brexit nerves, but with Wall Street pointing to a post-Thanksgiving rise MSCI's main world index was readying another all-time high.

"Risk sentiment is in reasonable nick because we've got vaccines and easy money," said Societe Generale (OTC:SCGLY) strategist Kit Juckes. "That is the underpinning of optimism."

It hadn't been all good news overnight. Australian shares ended down 0.5% and Treasury Wine Estates (OTC:TSRYF) was whacked 11.25% as China slapped new tariffs on Australian wine, the latest move in the countries' long-running trade spat.

But shares in China still rose 0.1% after data there showed industrial profits surged at the fastest pace since early 2017. South Korean stocks and Japan's Nikkei both rose 0.3% too, albeit in choppy trade.

British drugmaker AstraZeneca's coronavirus drug was touted as a "vaccine for the world" due to its inexpensive cost, but the efficacy of the vaccine is now facing more intense scrutiny, which experts say could delay its approval.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.

"With global (coronavirus) case numbers having now topped 60 million... there is certainly some rough terrain ahead for the global recovery, and that can create economic scarring," analysts at ANZ Bank wrote in a memo.

VIRUS VS VACCINE

U.S. hospitalizations for COVID-19 are at a record and experts warn that Thanksgiving gatherings could lead to further infections and deaths.

More than 20 million people across England will be forced to live under the toughest restrictions even after a national lockdown ends on Dec. 2. Partial lockdowns in some European countries have also raised concern about economic growth.

The European Central Bank's chief economist highlighted these concerns, saying there were "some worrying signals" in financing conditions in Europe for small and medium-sized enterprises, which pushed European bond yields lower.

German 10-year Bund yields traded near two-week lows on Friday, while Portugal's 10-year government bond yields touched zero for the first time.

The euro, which last bought $1.1924, showed little reaction because currency traders have largely priced in expectations for additional ECB easing next month.

The dollar, which has fallen more than 2.2% so far this month as global sentiment has surged, lessening demand for the safe-haven currency, was near its lowest in nearly three months.

"Surely euro-dollar can't break through $1.20 without good news on the (Brexit) trade deal," Societe Generale's Juckes added.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The yield on benchmark 10-year Treasury notes fell to 0.8586% as some investors sought the safety of holding government debt.

In commodity markets, copper, another key gauge of global economic sentiment due to its use in infrastructure, hit a near 7-1/2 month high. Oil, though up nearly 30% this month, dipped overnight on oversupply concerns, but Brent recovered in London to rise to $48 per barrel.

Bitcoin, the world's biggest cryptocurrency, edged up to $17,256 on Thursday after tumbling 8.4% in the previous session, having failed to take out its record high of $19,666.

The cryptocurrency showed little reaction to a report in the Financial Times that Facebook (NASDAQ:FB) will launch its own Libra digital currency in limited format next year.

Bitcoin has rallied around 140% this year, fuelled by demand for riskier assets.

Latest comments

Oh no, Hopes have become Doubts.  But this market only works with Hopes and greed so let's see how far greed gets us......
it works like this: hope,hope,euphoria, doubts,hope,hope...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.